期刊文献+

坎地沙坦酯联合二甲双胍治疗原发性高血压伴胰岛素抵抗的疗效

下载PDF
导出
摘要 目的观察坎地沙坦酯联合二甲双胍治疗高血压伴胰岛素抵抗(insulin resistance,IR)病人的降压疗效和对胰岛素抵抗的影响。方法将72例高血压伴IR的病人分为治疗组和对照组。治疗组给予坎地沙坦酯和二甲双胍治疗,对照组单给予坎地沙坦酯治疗疗程均为4个月。观察两组治疗前后的血压、血糖、胰岛素敏感性指数的变化及不良反应。结果治疗组服药后餐后2h血糖、餐后2h胰岛素均下降,胰岛素敏感指数升高,与对照组比较差异均有统计学意义(P<0.05或P<0.01)。两组服药后收缩压和舒张压均下降,但治疗组收缩压下降程度较对照组明显。两组在治疗期间均未出现明显的不良反应。结论采用坎地沙坦酯和二甲双胍治疗高血压伴IR病人,可明显改善病人的胰岛素抵抗,有利于提高降压疗效。
出处 《心脑血管病防治》 2009年第4期286-287,共2页 CARDIO-CEREBROVASCULAR DISEASE PREVENTION AND TREATMENT
  • 相关文献

参考文献5

二级参考文献12

  • 1王薇,赵冬,刘静,孙佳艺,吴桂贤,曾哲淳,刘军,秦兰萍,吴兆苏.中国35~64岁人群血压水平与10年心血管病发病危险的前瞻性研究[J].中华内科杂志,2004,43(10):730-734. 被引量:147
  • 2华琦,汤哲.北京市老年人群体重、血脂、血压及血糖水平的调查与分析[J].中华内科杂志,1997,36(1):18-20. 被引量:98
  • 3Schwartz GG, Olsson AG, Szarek M, et al. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome : an analysis of the myocardial ischemia reduction with aggressive cholesterol low-ering(MIRACL) trial[ J]. Diabetes Care ,2005,28:2508 - 2513.
  • 4Keech A, Simes R J, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus ( the FIELD study ) : randomised controlled trial [ J ]. Lancet ,2005 ,366 : 1849 - 1861.
  • 5ADVANCE Collaborative Group, Patel A, MacMabon S, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus ( the ADVANCE trial ) : a randomised controlled trial[J]. Lancet ,2007,370:829 - 840.
  • 6Nissen SE,Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[ J]. N Engl J Med, 2007,356,2457 - 2471.
  • 7Home PD. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis[J]. N Engl J Med ,2007,357,28 - 38.
  • 8Wadden TA. Randomized trial of lifestyle modification and pharmacotherapy for obesity [ J ]. N Engl J Med, 2005,353,2111 - 2120.
  • 9Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid 21 receptor blocker rimanabant on weight reduction and cardiovascular risk factors in overweight patients: 12-year experience from the RIO-Europe study [ J ]. Lancet, 2005,365 : 1389 - 1397.
  • 10Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker,on weight and cardiometabolic risk factors in overweight or obese patients : RIO North America: a randomized controlled trial [ J ]. JAMA, 2006, 295 : 761 - 775.

共引文献496

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部